These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 15893419

  • 1. Fecal Adnab-9 binding as a risk marker for colorectal neoplasia.
    Yuan M, Xhang X, Leu Y, Xu Y, Ullah N, Lawson M, Tobi M.
    Cancer Lett; 2006 Apr 08; 235(1):48-52. PubMed ID: 15893419
    [Abstract] [Full Text] [Related]

  • 2. Measurement of fecal pyruvate kinase type M2 (tumor M2-PK) concentrations in patients with gastric cancer, colorectal cancer, colorectal adenomas and controls.
    Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU.
    Anticancer Res; 2003 Apr 08; 23(2A):851-3. PubMed ID: 12820312
    [Abstract] [Full Text] [Related]

  • 3. Fecal lysozyme: an unreliable marker for colorectal cancer.
    Dubrow R, Kim CS, Eldred AK.
    Am J Gastroenterol; 1992 May 08; 87(5):617-21. PubMed ID: 1595650
    [Abstract] [Full Text] [Related]

  • 4. Detection of gastric cancer and premalignant lesions by novel marker glycoprotein 87 using monoclonal antibody Adnab-9.
    Qiao SX, Yuan M, Liu YL, Lin XS, Zhang XP, Tobi M.
    Cancer Epidemiol Biomarkers Prev; 2003 Oct 08; 12(10):1095-9. PubMed ID: 14578149
    [Abstract] [Full Text] [Related]

  • 5. Fecal cyclooxygenase 2 plus matrix metalloproteinase 7 mRNA assays as a marker for colorectal cancer screening.
    Takai T, Kanaoka S, Yoshida K, Hamaya Y, Ikuma M, Miura N, Sugimura H, Kajimura M, Hishida A.
    Cancer Epidemiol Biomarkers Prev; 2009 Jun 08; 18(6):1888-93. PubMed ID: 19505922
    [Abstract] [Full Text] [Related]

  • 6. Asymptomatic colorectal neoplasia and fecal characteristics: a case-control study of subjects participating in the nottingham fecal occult blood screening trial.
    Little J, Owen RW, Fernandez F, Hawtin PG, Hill MJ, Logan RF, Thompson MH, Hardcastle JD.
    Dis Colon Rectum; 2002 Sep 08; 45(9):1233-41. PubMed ID: 12352242
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia.
    Lane JM, Chow E, Young GP, Good N, Smith A, Bull J, Sandford J, Morcom J, Bampton PA, Cole SR.
    Gastroenterology; 2010 Dec 08; 139(6):1918-26. PubMed ID: 20723544
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps.
    Leung WK, To KF, Man EP, Chan MW, Hui AJ, Ng SS, Lau JY, Sung JJ.
    Am J Gastroenterol; 2007 May 08; 102(5):1070-6. PubMed ID: 17378912
    [Abstract] [Full Text] [Related]

  • 11. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer.
    Melotte V, Lentjes MH, van den Bosch SM, Hellebrekers DM, de Hoon JP, Wouters KA, Daenen KL, Partouns-Hendriks IE, Stessels F, Louwagie J, Smits KM, Weijenberg MP, Sanduleanu S, Khalid-de Bakker CA, Oort FA, Meijer GA, Jonkers DM, Herman JG, de Bruïne AP, van Engeland M.
    J Natl Cancer Inst; 2009 Jul 01; 101(13):916-27. PubMed ID: 19535783
    [Abstract] [Full Text] [Related]

  • 12. Cellular distribution of a colonic adenoma-associated antigen as defined by monoclonal antibody Adnab-9.
    Tobi M, Maliakkal BJ, Alousi MA, Voruganti V, Shafiuddin M, Yang S, Gesell MS, An T, Hatfield JS, Fligiel S.
    Scand J Gastroenterol; 1992 Sep 01; 27(9):737-42. PubMed ID: 1411278
    [Abstract] [Full Text] [Related]

  • 13. Testing of multiple samples increases the sensitivity of stool decay-accelerating factor test for the detection of colorectal cancer.
    Mizuno M, Mizuno M, Iwagaki N, Nasu J, Okazaki H, Yamamoto K, Okada H, Tsuji T, Fujita T, Shiratori Y.
    Am J Gastroenterol; 2003 Nov 01; 98(11):2550-5. PubMed ID: 14638362
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Fecal pyruvate kinase concentrations (ELISA based on a combination of clone 1 and clone 3 antibodies) for gastric cancer screening.
    Hardt PD, Toepler M, Ngoumou B, Rupp J, Kloer HU.
    Anticancer Res; 2003 Nov 01; 23(2A):855-7. PubMed ID: 12820313
    [Abstract] [Full Text] [Related]

  • 18. Faecal tumour pyruvate kinase M2: not a good marker for the detection of colorectal adenomas.
    Shastri YM, Stein JM.
    Br J Cancer; 2008 Oct 21; 99(8):1366; author reply 1367. PubMed ID: 18827821
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.